Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

A positive end to a dull week
Fri, 29 May Closing

Indian equity markets traded firm in today's session despite negative global cues. The Indian indices began the day's proceedings on a firm note and the afternoon session saw them inching upwards as buying intensified across index heavyweights. The BSE Sensex closed higher by 358 points while NSE-Nifty closed higher by 115 points. BSE Mid Cap and BSE Small Cap outperformed today, closing 1.2% and 1.4% higher respectively. Barring realty, all other BSE sectoral indices were trading in the green. Among them, auto index gained the most, followed by infrastructure and healthcare.

Asian markets finished mixed. The Nikkei 225 gained 0.06%, while the Shanghai Composite led the Hang Seng lower. They fell 0.18% and 0.17% respectively. European stocks drop as Greece worries persist. The rupee was trading strong by at 63.76 in the post noon session.

As per a leading financial daily, the US subsidiary of Glenmark Pharmaceuticals, Glenmark Pharmaceuticals Inc. has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Desmopressin Acetate. The tablets are used in the treatment of diabetes. Desmopressin Acetate is sold under the trademark DDAVP. Reportedly, sales data for the 12 month period ending March 2015, the DDAVP market achieved annual sales of approximately US$ 72.1 million. Glenmark's current portfolio consists of 97 products authorized for distribution in the U.S. marketplace and 68 ANDA's pending approval with the USFDA. The stock of Glenmark ended up by 2.34% today.

According to a leading financial daily, Crompton Greaves has received non-binding proposals from international entities for acquiring the company's European, North American and Indonesian power divisions. It has also received offers for the Canadian power and the American transportation automation business. In April, Crompton Greaves' consumer electrical business was sold to Advent International Corp and Singapore's Temasek Holdings for Rs 20 bn. Reportedly, Avantha Holdings, promoter of Crompton Greaves has stated that Crompton Greaves Consumer Electricals Ltd (CGCEL) will be demerged into a standalone company and listed on the stock exchanges. Shares of Crompton Greaves ended the day in green (up 1.81%) at the BSE.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "A positive end to a dull week". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.